Our strategy

Lundbeck has made significant progress since 2015 based on a clear and focused strategy. Today, we are in a good position to continue our solid performance: We are focusing on our core strengths, we have several newly marketed products with many years of market exclusivity, we have a promising R&D portfolio, and we have a profitable and competitive platform.

We have a clear vision
Lundbeck strives for global leadership in psychiatry and neurology by improving the lives of patients. This vision is based on our ambitions, our leading competencies in the field, and our passion about making a difference for people living with psychiatric and neurological disorders. 

We invent new treatments and improve patients’ access to them. Today, our product portfolio includes some of the best antidepressants and antipsychotics available. Within neurology, we have a promising portfolio of novel research projects with the potential to become leading treatments within Alzheimer’s and Parkinson’s diseases.

Every year, treatments invented by Lundbeck reach more than 50 million patients around the world.

We focus on four disease areas
We focus our efforts on depression, schizophrenia, Alzheimer’s and Parkinson’s diseases. Within these four disease areas, we have expertise throughout the value chain, a proven ability to bring novel treatments to the market and a promising portfolio of R&D projects, with the potential to improve patients’ lives.

These diseases are among the most disabling conditions in the world, representing the highest burden for society. Focusing on these four disease areas gives Lundbeck the opportunity to make a difference to millions of people all over the world.

If we are successful in improving treatments for patients in these four disease areas, it will also strengthen Lundbeck’s competitiveness and performance. The global pharmaceutical market for the four diseases is around USD 45 billion, which is approximately 20 times Lundbeck’s annual revenue.

We will capture full value
We will fill our pipeline with in-house inventions and early external innovation. This independent approach will ensure that we capture the full value of our products. Research into the brain costs more, takes longer and fails at a higher rate than most other medical research. But if we can launch new products with global rights, we will be able to create long-term sustainable value. 

We have several important and valuable partnerships and will continue to benefit greatly from the collaboration with partners in the years to come. Going forward, however, we will also strive to develop and commercialize innovative and improved treatments on our own.

We aim for global, profitable growth
Lundbeck will continue to focus on profitability. Today, we have a strong and competitive presence in the US, the world’s biggest pharmaceutical market. We still see great opportunities for expanding our business in countries such as China and Japan, we will seek further opportunities in emerging markets and we will continue to optimize our presence in established markets.

With our focused strategy, we will be able to create the most value for patients, societies and shareholders. Lundbeck will continue to be an attractive and engaging workplace, conducting research in potentially breakthrough treatments, growing the business profitably.

How we create value
Our focused strategy consists of a simple framework: our vision describes what we strive for; our principles are based on Lundbeck’s unique culture and guide our actions; and our strategic objectives define the strategic focus for decisions and execution of the strategy in the years to come.

Strategic objectives

  • Four disease areas: We will strive for leadership in the treatment of depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
  • Innovation: We will develop innovative treatments that address unmet patient needs.
  • Globalization: We will expand and optimize our global organization.
  • Profitability: We will grow our business with a strong focus on profitability created by independent development and commercialization of future products.
  • Organization: Lundbeck will be a specialized company with strong cross-functional collaboration.


Lundbeck strives for global leadership in psychiatry and neurology by improving the lives of patients.

Our principles

Our principles are based on Lundbeck’s unique culture and guide the daily decisions and behaviour of people in the company.


We are focused on innovating treatments for depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease while creating value for all our stakeholders.


We are passionate about helping patients and communities affected by psychiatric and neurological disorders.


We are responsible and overcome challenges by demonstrating respect, open-mindedness and integrity.

Annual Report 2017

Read our Annual Report 2017


Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.